In a safety net population HPV4 vaccine adherence worsens as BMI increases

Obesity adversely inhibits antibody response to vaccination. Three doses of HPV4 may or may not provide adequate long term protection against HPV 16/18 in obese females. The aim of this study was to determine whether adherence to HPV4 vaccination in a safety net population was reduced with increasin...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2014-07, Vol.9 (7), p.e103172-e103172
Main Authors: Harper, Diane M, Else, Britney M, Bartley, Mitchell J, Arey, Anne M, Barnett, Angela L, Rosemergey, Beth E, Paynter, Christopher A, Verdenius, Inge, Harper, Sean M, Harris, George D, Groner, Jennifer A, Malnar, Gerard J, Wall, Jeffrey, Bonham, Aaron J
Format: Article
Language:English
Subjects:
Adhesion
Adolescent
Adult
Alphapapillomavirus - immunology
Antibody response
Biology and Life Sciences
Body mass
Body Mass Index
Body size
Body weight
Cervical cancer
Child
Demographics
Dosage
Female
Females
Human papillomavirus
Humans
Kansas - epidemiology
Medicine and Health Sciences
Obesity
Overweight
Papillomavirus infections
Papillomavirus Infections - epidemiology
Papillomavirus Infections - prevention & control
Papillomavirus Vaccines - administration & dosage
Papillomavirus Vaccines - immunology
Patient Compliance
Pregnancy
Prospective Studies
Risk analysis
Risk Factors
Safety
Teenagers
Vaccination
Vaccines
Womens health
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Obesity adversely inhibits antibody response to vaccination. Three doses of HPV4 may or may not provide adequate long term protection against HPV 16/18 in obese females. The aim of this study was to determine whether adherence to HPV4 vaccination in a safety net population was reduced with increasing body mass index (BMI). We designed a historical prospective study evaluating the number and dates of HPV4 dosing that occurred from July 1, 2006 through October 1, 2009 by the demographic characteristics of the 10-26 year old recipient females. The defined dosing intervals were adapted from the literature and obesity categories were defined by the WHO. 1240 females with BMI measurements received at least one dose of HPV4; 38% were obese (class I, II and III) and 25% were overweight. Females with normal BMI received on-time triplet dosing significantly more often than did the obese class II and III females (30% vs. 18%, p
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0103172